US › Healthcare

InMed Pharmaceuticals Inc (INM)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.49+2.05%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$659.8M
Revenue YoY
+52203.4%
Net profit
$-3.0M
Profit YoY
-39.9%
EPS
$-0.73
Net margin
-0.4%

Key statistics

Market cap
$7.8M
Forward P/E
0.0
P/B
1.14
Book value
$2.08
EPS (TTM)
$-1.47
52-week high
$2.50
52-week low
$0.57
50-day MA
$1.59
200-day MA
$1.24
Beta
0.95

Analyst view

with an average price target of $20.00.

Shareholding

Insiders
0.12%
Institutions
70.72%

Largest institutional holders

FundStake
Sabby Management LLC6.65%
Citadel Advisors Llc1.42%
Virtu Financial LLC0.60%
TWO SIGMA SECURITIES, LLC0.56%
UBS Group AG0.24%
Private Wealth Management Group LLC0.15%
SBI Securities Co Ltd0.01%
Banque Cantonale Vaudoise0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for InMed Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.